Baseline disease characteristics in the induction phase of the ALMS trial
| Characteristic | Total (N= 370) |
| Anti-dsDNA (n (%)) | |
| High | 310 (83.78) |
| NA | 9 (2.43) |
| Normal | 51 (13.78) |
| ANA (n (%)) | |
| High | 186 (50.27) |
| NA | 123 (33.24) |
| Normal | 61 (16.49) |
| Complement C3 (n (%)) | |
| High | 2 (0.54) |
| Low | 274 (74.05) |
| NA | 7 (1.89) |
| Normal | 87 (23.51) |
| Complement C4 (n (%)) | |
| High | 4 (1.08) |
| Low | 215 (58.11) |
| NA | 8 (2.16) |
| Normal | 143 (38.65) |
| Haemoglobin (n (%)) | |
| High | 2 (0.54) |
| Low | 212 (57.30) |
| NA | 16 (4.32) |
| Normal | 140 (37.84) |
| Lymphocytes (n (%)) | |
| High | 15 (4.05) |
| Low | 74 (20.00) |
| NA | 21 (5.68) |
| Normal | 260 (70.27) |
| Platelets (n (%)) | |
| High | 43 (11.62) |
| Low | 12 (3.24) |
| NA | 24 (6.49) |
| Normal | 291 (78.65) |
| Immunoglobulin IgG (n (%)) | |
| High | 85 (22.97) |
| Low | 67 (18.11) |
| NA | 1 (0.27) |
| Normal | 217 (58.65) |
| Lupus anticoagulant (n (%)) | |
| NA | 14 (3.78) |
| Negative | 309 (83.51) |
| Positive | 47 (12.70) |
| Anticardiolipin IgM (n (%)) | |
| High | 25 (6.76) |
| NA | 103 (27.84) |
| Normal | 242 (65.41) |
| Anticardiolipin IgG (n (%)) | |
| High | 67 (18.11) |
| NA | 103 (27.84) |
| Normal | 200 (54.05) |
| SLICC/ACR damage index (without renal category) (n (%)) | |
| 0 | 195 (52.70) |
| 1 | 50 (13.51) |
| >1 | 29, (7.84) |
| NA | 96 (25.95) |
| SLEDAI score (mean±SD) | 15.28±6.78 |
| BILAG general A or B (n (%)) | 62 (16.80) |
| BILAG haematology A or B (n (%)) | 138 (37.30) |
| BILAG cardiorespiratory A or B (n (%)) | 21 (5.69) |
| BILAG mucocutaneous A or B (n (%)) | 108 (29.19) |
| BILAG musculoskeletal A or B (n (%)) | 62 (16.80) |
| BILAG neuropsychiatric A or B (n (%)) | 8 (21.62) |
| BILAG renal A or B (n (%)) | 367 (99.19) |
| BILAG vasculitis A or B (n (%)) | 19 (5.14) |
ALMS, Aspreva Lupus Management Study; BILAG, British Isles Lupus Assessment Group; NA, data not available /missing; SLEDAI, Systemic Lupus Erythematosus Disease Activity; SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology.